Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Patients With Advanced Colorectal Cancer

NCT00004193 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT00004193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Patients With Advanced Colorectal Cancer
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 1999
Completion date
November 30, 2000
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer